Pancreatic cancer remains one of the most difficult cancers to treat, particularly in metastatic disease. Despite FOLFIRINOX and gemcitabine-Abraxane, survival gains remain limited, while significant treatment-related toxicities can require dose reductions, treatment delays, or discontinuation.

Onselex’s ONX-1006 encapsulates paclitaxel in a stable polymeric nanoparticle designed to minimize systemic exposure to paclitaxel and normal cells while increasing tumor delivery and accumulation.

ONX-1006 established a No Observed Adverse Effect Level (NOAEL) equivalent to 750+ mg of paclitaxel for a 60 kg adult—about 3.75× a typical 200 mg Abraxane dose—without treatment-related adverse toxicological findings, supporting a substantially greater safety margin and repeated, continuous treatment.

ONX-1006 also demonstrated strong antitumor efficacy in pancreatic cancer xenograft models, achieving 20% greater tumor reduction than Abraxane at the same total weekly paclitaxel dose. TUNEL analysis also confirmed the highest level of tumor-cell death in the ONX-1006 group.

Based on extrapolation of its preclinical findings, Onselex has established development goals of 90% to 100% tumor elimination and a 70% one-year survival rate.

Onselex’s nanoparticle platform extends across solid tumors and neurological diseases, aiming to provide effective treatment while preserving quality of life and normal daily living.

We welcome investors and strategic partners to join us on this journey to advance a therapeutic innovation that could save tens of millions of lives worldwide.

To learn more about Onselex or discuss an investment or strategic partnership opportunity, please contact us by email.

Thank you for your consideration. Ernie Shin